PROTOCOL SUMMARY FOR PATIENTS

View Professional Summary

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors


Basic Trial Information

Protocol Phase:Phase I
Study Category:Treatment
Current Protocol StatusActive
Age18 and 0ver
Protocol SponsorPharmaceutical/Industry
Primary IDIMGN853-0401
Other IDNCT01609556
Special Category

TRIAL DESCRIPTION

Purpose:
Eligibility:
Treatment Intervention:
Patient Disclaimer: